0000950170-23-046504.txt : 20230905
0000950170-23-046504.hdr.sgml : 20230905
20230905173433
ACCESSION NUMBER: 0000950170-23-046504
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230901
FILED AS OF DATE: 20230905
DATE AS OF CHANGE: 20230905
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Boyle Kevin S. Sr.
CENTRAL INDEX KEY: 0001880600
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-33038
FILM NUMBER: 231237077
MAIL ADDRESS:
STREET 1: C/O ZIOPHARM ONCOLOGY, INC.
STREET 2: ONE FIRST AVENUE, PARRIS BLDG 34
CITY: BOSTON
STATE: MA
ZIP: 02129
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Alaunos Therapeutics, Inc.
CENTRAL INDEX KEY: 0001107421
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 841475642
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 8030 EL RIO STREET
CITY: HOUSTON
STATE: TX
ZIP: 77054
BUSINESS PHONE: (346) 355-4099
MAIL ADDRESS:
STREET 1: 8030 EL RIO STREET
CITY: HOUSTON
STATE: TX
ZIP: 77054
FORMER COMPANY:
FORMER CONFORMED NAME: ZIOPHARM ONCOLOGY INC
DATE OF NAME CHANGE: 20050919
FORMER COMPANY:
FORMER CONFORMED NAME: EASYWEB INC
DATE OF NAME CHANGE: 20010213
4
1
ownership.xml
4
X0508
4
2023-09-01
0001107421
Alaunos Therapeutics, Inc.
TCRT
0001880600
Boyle Kevin S. Sr.
C/O ALAUNOS THERAPEUTICS, INC.
8030 EL RIO ST.
HOUSTON
TX
77054
true
true
false
false
Chief Executive Officer
true
Common Stock
2023-09-01
4
S
false
68014
0.1403
D
798236
D
Represents the sale of shares of Common Stock pursuant to a "sell-to-cover" transaction in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of shares of restricted stock previously granted to the Reporting Person. This sale was effected pursuant to a plan adopted on November 17, 2022 in accordance with Rule 10b5-1 and does not represent a discretionary sale by the reporting person.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.14 to $0.1424, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
/s/ Melinda Lackey, Attorney-in-Fact
2023-09-05